Evidence map›Paper›PMID 35578294›Full record

ReviewItalian journal of pediatrics2022

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).

Elio Novembre, Mariangela Tosca, Carlo Caffarelli, Mauro Calvani, Fabio Cardinale, Riccardo Castagnoli, Elena Chiappini, Claudio Cravidi, Michele Miraglia Del Giudice, Marzia Duse and 6 more

Open access · goldAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Italian journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Year 2022: exploring COVID-19 pandemic in children.Italian journal of pediatrics · 2023
    Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Elio NovembreAllergy Unit, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy.
Mariangela ToscaAllergy Center, Istituto Giannina Gaslini, Genoa, Italy.
Carlo CaffarelliPediatric Clinic, Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, Parma, Italy. carlo.caffarelli@gmail.com.ORCID http://orcid.org/0000-0001-7710-6995
Mauro CalvaniOperative Unit of Pediatrics, S. Camillo-Forlanini Hospital, Rome, Italy.
Fabio CardinalePediatric Unit, Azienda Ospedaliero-Universitaria "Policlinico- Giovanni XXIII, Bari, Italy.
Riccardo CastagnoliPediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Elena ChiappiniPaediatric Infectious Diseases Unit, Department of Health Sciences, Anna Meyer Children's University Hospital, University of Florence, Florence, Italy.
Claudio CravidiATS Pavia, Pavia, Italy.
Michele Miraglia Del GiudiceDepartment of Woman and Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.
Marzia DuseDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Amelia LicariPediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Sara MantiPediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
Alberto MartelliPediatrician at the University of Pavia, Pavia, Italy.
Giampaolo RicciAlma Mater Studiorum, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Giuseppe PingitorePediatrician and Allergist, Rome, Italy.
Gian Luigi MarsegliaPediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
University of Pavia · ITMeyer Children's Hospital · ITCarlo Forlanini Hospital · ITIstituto Giannina Gaslini · ITOspedale Pediatrico Giovanni XXIII · ITSapienza University of Rome · ITUniversity of Bologna · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Catania · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.

Indexed as

AnaphylaxisAsthmaCOVID-19BNT162 VaccineChildCOVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2BNT162 VaccineCOVID-19 VaccinesRNA, MessengerAdverse eventAllergyBNT162b2ChildrenCOVID-19mRNA vaccinePfizer BioNtechSARS-CoV-2Side effectVaccine

Identifiers

PMID35578294
PMCPMC9109428
OpenAlexW4280534132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.